primeLine Solutions now offers SupremeRAID™, the revolutionary GPU-based NVMe RAID controller from GRAID Technology, to deliver custom HPC storage solutions with impressive performance for demanding workloads. SANTA CLARA, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — primeLine Solutions GmbH, a leader in German tailor-made high performance servers, now incorporates SupremeRAID™ GPU

Fusion vessel trial ring VANCOUVER, British Columbia and LONDON, Oct. 20, 2022 (GLOBE NEWSWIRE) — Construction of General Fusion’s demonstration machine, which is being built at the UK Atomic Energy Agency’s Culham Campus, advanced significantly with the fabrication of an at-scale fusion vessel trial ring by Sheffield Forgemasters. This critical

SEATTLE and SINGAPORE, Oct. 20, 2022 (GLOBE NEWSWIRE) —  Remitly Global, Inc. (NASDAQ: RELY) (“Remitly”), a leading digital financial services provider for immigrants and their families in over 170 countries around the world, today announced key business milestones in the Asia-Pacific (APAC) region. Remitly has expanded its global footprint to

Nuvei brings new instant settlement options to merchants globally, aiding regions where instant account-to-account payment solutions are not available Montreal, Oct. 20, 2022 (GLOBE NEWSWIRE) — Nuvei Corporation (“Nuvei” or the “Company”) (Nasdaq: NVEI) (TSX: NVEI), the Canadian fintech company, announces today that its merchant client base can now benefit

The company offers innovative and accessible diagnostic solutions that improve IVF success rates Inti Labs logo PALO ALTO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Inti Labs, Inc. (Inti Labs) today announces its official launch and ambitious long-term vision to overcome infertility. The company is focused on developing a range

October 20, 2022 FDA 510(k) clearance for AI-enabled Philips MR for Calculating Attenuation (MRCAT) Head and Neck radiotherapy application expands range of MR-only workflows MacroMedics’ positioning mask system [1] now compatible with Philips MR Head Neck Coil, helping to improve patient experience and treatment outcomes Amsterdam, the Netherlands – Royal

– First presentation of BPT264, the only Treg-targeting IL-2 for autoimmune disease that is both IL2Rα-enhanced and IL2Rβ-dead, displaying best-in-class preclinical properties — – Introduction of BPT323, a cutting-edge, multifunctional immunocytokine combining TNFα blockade and selective Treg expansion for the treatment of autoimmune disease — SAN DIEGO and BASEL, Switzerland,